Atypical Presentation of Dowling-Degos Disease with Novel and Recurrent Mutations in POFUT1

Weilong Zhong,J. Liu,H. Wang,Xia Dou,Bo Yu,Zhimiao Lin,Yanling Yang
DOI: https://doi.org/10.1111/ced.13649
2018-01-01
Clinical and Experimental Dermatology
Abstract:1 Kopf AW, Morrill SD, Silberberg I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965; 92: 14–33; discussion 33–5. 2 Yang Y, Li S, Zhu G et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus. J Dermatol Sci 2017; 87: 50–9. 3 Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 2017; 76: 745–53.e19. 4 Rothstein B, Joshipura D, Saraiya A et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 2017; 76: 1054–60.e1. 5 Liu LY, Strassner JP, Refat MA et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 2017; 77: 675–82.e1.
What problem does this paper attempt to address?